– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs,...
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class...
“ Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 “ “ Achieved $75 million...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
-Â With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada™s operational growth - BOSTON, Jan. 03,...
“ Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 “ “ ENTR-601-44 clinical development program remains on track with data readout expected in second...
Despite Entrada Therapeutics' efforts to persuade the FDA with additional information, the regulatory agency has rejected the company's attempts to lift the nearly yearlong clinical hold on its leading Duchenne muscular dystrophy (DMD) candidate.